A Phase 2 interventional study of ZW25 (Zanidatamab) and Capecitabine in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer, sponsored by Jazz Pharmaceuticals. Completed at 23 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-04.
Sponsored by Jazz Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 28 studies testing cisplatin in Biliary Tract Neoplasms — 7 open to participants now, 10 under way, 2 of them phase 3. Cisplatin · Biliary Tract Neoplasms.
Among the 28 studies testing cisplatin in Biliary Tract Neoplasms, this one is the 10th largest by enrollment, is one of 4 that started in 2019, is one of 15 in phase 2, and was the 15th registered.
521 studies on the registry are indexed under Biliary Tract Neoplasms; 201 are open to participants now.
Browse Biliary Tract Neoplasms studies →7 of the 28 studies testing cisplatin in Biliary Tract Neoplasms are open now, in 5 countries. Recruiting first, the newest first:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Sites in China
Ages 18–75
University of Maryland, Baltimore · Sites in United States
Ages 21+
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd · Sites in China
Ages 18–75
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · Sites in United States
Ages 18+
Gruppo Oncologico del Nord-Ovest · Sites in Italy
Ages 18–75
By country, each count listing its studies:
Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →
Of the 140 Biliary Tract Neoplasms studies recruiting now, 80 (57%) set no upper age limit and 37 (26%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
28 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 20 · Phase 3 4
First in 2002; this study’s year is marked. 4 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 74 is above the median of 58 across 429 interventional studies indexed under Biliary Tract Neoplasms.
Median enrollment 50 across the 28 interventional studies. Of the 12 that completed or were terminated, 4 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 28 have an industry lead sponsor. The 10 most frequent:
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
Jazz Pharmaceuticals has 4 studies filed under Biliary Tract Neoplasms — fewer than ten, so there is no comparison to draw.
2 of the studies testing cisplatin in Biliary Tract Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02632305AHS Cancer Control AlbertaA Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer | 2026-12 |
| NCT07831993The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolSintilimab Plus NALIRIFOX or Gemcitabine-Cisplatin as First-Line Treatment for Metastatic Biliary Tract Cancer | 2027-06-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 28 studies testing cisplatin in Biliary Tract Neoplasms, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter, global, Phase 2, open-label, 2-part, first-line study to investigate the safety, tolerability, and anti-tumor activity of ZW25 (zanidatamab) plus standard first-line combination chemotherapy regimens for selected gastrointestinal (GI) cancers. Eligible patients include those with unresectable, locally advanced, recurrent or metastatic HER2-expressing gastroesophageal adenocarcinoma (GEA), biliary tract cancer (BTC), or colorectal cancer (CRC).
Part 1 of the study will first evaluate the safety and tolerability of ZW25 plus standard first-line combination chemotherapy (XELOX, FP, or mFOLFOX6 for GEA; mFOLFOX6 with or without bevacizumab for CRC; and CisGem for BTC) and will confirm the recommended dosage (RD) of ZW25 when administered in combination with each of these multi-agent chemotherapy regimens. Then, Part 2 of the study will evaluate the anti-tumor activity of ZW25 plus combination chemotherapy in HER2-expressing GEA, BTC, and CRC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Disease diagnosis:
Tumor measurements as per (RECIST) version 1.1:
Exclusion:
Prior systemic anti-cancer therapy (including products) except prior /neoadjuvant therapy, which must be completed at least 6 months prior to first study treatment dosing. For subjects with BTC and CRC the following additional exceptions apply:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CD4 count
The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ZW25 plus fluorouracil (5-FU) and cisplatin
Drug: ZW25 (Zanidatamab) · Drug: Cisplatin · Drug: Fluorouracil
ZW25 plus 5-FU, leucovorin, and oxaliplatin
Drug: ZW25 (Zanidatamab) · Drug: Fluorouracil · Drug: Leucovorin · Drug: Oxaliplatin
ZW25 plus capecitabine and oxaliplatin
Drug: ZW25 (Zanidatamab) · Drug: Capecitabine · Drug: Oxaliplatin
ZW25 plus 5-FU, leucovorin, oxaliplatin, and bevacizumab
Drug: ZW25 (Zanidatamab) · Drug: Fluorouracil · Drug: Leucovorin · Drug: Oxaliplatin · Drug: Bevacizumab
ZW25 plus cisplatin and gemcitabine
Drug: Cisplatin · Drug: Gemcitabine
* Part 1: administered IV at dose levels and schedules determined by the Safety Monitoring Committee (SMC) * Part 2: RD identified in Part 1
Administered orally twice daily (PO bid)
Administered IV
Administered IV
Administered IV
Administered IV
Administered IV
Administered IV
Number of Participants Reporting Dose-limiting Toxicities (DLTs) (Part 1)
DLTs include adverse events considered to be related to study treatment, including the evaluated dose level of ZW25, any component or combination of the components of a chemotherapy regimen, or the combination of ZW25 plus a chemotherapy regimen.
Time frame: Cycle 1 of treatment for all Part 1 treatment regimens (each cycle is 21 days for the XELOX, FP, and CisGem regimens; 28 days for the mFOLFOX6 regimens)
Number of Participants Reporting Treatment-emergent Adverse Events (Part 1; Parts 1 and 2)
AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 (v5.0).
Time frame: From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months
Number of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2)
Grades of laboratory abnormalities were defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.
Time frame: From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months
Confirmed Objective Response Rate (ORR) (Parts 1 and 2)
Number of participants who achieved a confirmed best response of either complete response (CR) or partial response (PR) during treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Time frame: From time from confirmed best response (CR or PR) to documented PD per RECIST 1.1 or death from any cause, whichever occurs first, up to approximately 68 months
Disease Control Rate (Parts 1 and 2)
Number of participants who achieved a best response of CR, PR, or stable disease (SD) during treatment per RECIST 1.1. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.
Time frame: From time from best response (CR, PR, SD) to documented PD per RECIST 1.1 or death from any cause, whichever occurred first, up to approximately 68 months
Duration of Response (Parts 1 and 2)
Median duration of response (in months) and range (minimum, maximum) are reported. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.
Time frame: From time from the first objective response (CR or PR) to documented PD per RECIST 1.1 or death from any cause, whichever occurred first, up to approximately 68 months
Clinical Benefit Rate (Parts 1 and 2)
Number of participants with SD for ≥ 24 weeks or a confirmed, best overall response of CR or PR per RECIST 1.1. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.
Time frame: From time from the response (SD ≥ 24 weeks, CR or PR) to documented PD per RECIST 1.1 or death from any cause, whichever occurs first, up to approximately 68 months
Progression-free Survival (Parts 1 and 2)
Median progression-free survival (in months) and range (minimum, maximum) are reported. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.
Time frame: From the time from the first dose of study treatment to the date of documented disease progression (per RECIST 1.1), clinical progression, or death from any cause, whichever occurred first, up to approximately 68 months
Overall Survival (Parts 1 and 2)
Median overall survival (in months) and range (minimum, maximum) are reported. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.
Time frame: From the time from the date of first dose of study treatment until the date of death from any cause, up to approximately 68 months
Incidence of Postbaseline Anti-drug Antibodies (ADAs) (Parts 1 and 2)
Number of participants who develop postbaseline ADAs are reported. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.
Time frame: Cycle 1 Day 1 up to 30 days after last dose, up to approximately 68 months (for ZW25 combined with XELOX, FP, or CisGem, each treatment cycle is 21 days; for ZW25 in combination with FOLFOX6 with or without bevacizumab, each treatment cycle is 28 days)
End of Infusion Concentration of ZW25 (Parts 1 and 2)
Pharmacokinetic (PK) parameters were assessed using noncompartmental procedures.
Time frame: Cycle 1 predose up to end of treatment, up to 68 months (for ZW25 combined with XELOX, FP, or CisGem, each treatment cycle is 21 days; for ZW25 in combination with FOLFOX6 with or without bevacizumab, each treatment cycle is 28 days)
Maximum Serum Concentration of ZW25 (Parts 1 and 2)
Pharmacokinetic (PK) parameters were assessed using noncompartmental procedures.
Time frame: Cycle 1 predose up to end of treatment, up to 68 months (for ZW25 combined with XELOX, FP, or CisGem, each treatment cycle is 21 days; for ZW25 in combination with FOLFOX6 with or without bevacizumab, each treatment cycle is 28 days)
Trough Concentration of ZW25 (Parts 1 and 2)
Pharmacokinetic (PK) parameters were assessed using noncompartmental procedures.
Time frame: Cycle 1, Day 15; Cycle 2, Days 1 and 15; Cycle 3, Days 1 and 15; Cycle 4, Day 1, and Cycle 6, Day 1 (for ZW25 combined with XELOX, FP, or CisGem, each cycle is 21 days; for ZW25 combined with FOLFOX6 with or without BEV, each cycle is 28 days)
Number of Participants Reporting Treatment-emergent Adverse Events (Part 1; Parts 1 and 2)
Adverse events (AEs) were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 (v5.0).
Time frame: From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months.
Number of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2)
Number of participants who experienced a maximum severity of Grade 3 or higher postbaseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.
Time frame: From the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months.
A total of 74 participants who met all inclusion criteria and no exclusion criteria were enrolled in the study at 20 clinic centers in 4 countries (United States, Canada, Chile, and South Korea).
| Milestone | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV |
|---|---|---|---|---|---|---|---|---|
| Started | 13 | 11 | 11 | 9 | 2 | 15 | 6 | 7 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 13 | 11 | 11 | 9 | 2 | 15 | 6 | 7 |
| Withdrew: Death | 9 | 7 | 4 | 6 | 1 | 7 | 1 | 0 |
| Withdrew: Study termination by sponsor | 4 | 4 | 5 | 1 | 1 | 5 | 5 | 4 |
| Withdrew: Withdrawal of consent | 0 | 0 | 2 | 2 | 0 | 3 | 0 | 3 |
DLTs include adverse events considered to be related to study treatment, including the evaluated dose level of ZW25, any component or combination of the components of a chemotherapy regimen, or the combination of ZW25 plus a chemotherapy regimen.
| Participants | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV |
|---|---|---|---|---|---|---|---|
| Number of Participants Reporting Dose-limiting Toxicities (DLTs) (Part 1) | 1 | 1 | 0 | 1 | 0 | 1 | 1 |
AEs were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 (v5.0).
| Participants | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV |
|---|---|---|---|---|---|---|---|---|
| Participants With At Least 1 TEAE (Part 1) | 13 | 7 | 6 | — | 2 | 6 | 6 | 7 |
| Participants With At Least 1 TEAE (Parts 1 and 2) | 13 | 11 | 11 | 9 | 2 | 15 | 6 | 7 |
Grades of laboratory abnormalities were defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.
| Participants | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV |
|---|---|---|---|---|---|---|---|---|
| Number of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2) | 8 | 7 | 6 | 2 | 0 | 10 | 2 | 1 |
Number of participants who achieved a confirmed best response of either complete response (CR) or partial response (PR) during treatment according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
| Participants | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV |
|---|---|---|---|---|---|---|---|---|
| Confirmed Objective Response Rate (ORR) (Parts 1 and 2) | 4 | 9 | 9 | 8 | 2 | 6 | 6 | 5 |
Number of participants who achieved a best response of CR, PR, or stable disease (SD) during treatment per RECIST 1.1. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.
| Participants | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV |
|---|---|---|---|---|---|---|---|---|
| Disease Control Rate (Parts 1 and 2) | 7 | 9 | 10 | 9 | 2 | 12 | 6 | 5 |
Median duration of response (in months) and range (minimum, maximum) are reported. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.
| months | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV |
|---|---|---|---|---|---|---|---|---|
| Duration of Response (Parts 1 and 2) | 28.06 (10.64 to NA) | 18.66 (2.79 to NA) | 11.01 (4.14 to NA) | 10.41 (4.04 to NA) | NA (6.83 to NA) | 13.26 (4.14 to NA) | NA (6.77 to NA) | NA (NA to NA) |
Number of participants with SD for ≥ 24 weeks or a confirmed, best overall response of CR or PR per RECIST 1.1. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.
| Participants | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV |
|---|---|---|---|---|---|---|---|---|
| Clinical Benefit Rate (Parts 1 and 2) | 4 | 9 | 10 | 8 | 2 | 9 | 6 | 5 |
Median progression-free survival (in months) and range (minimum, maximum) are reported. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.
| months | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV |
|---|---|---|---|---|---|---|---|---|
| Progression-free Survival (Parts 1 and 2) | 12.02 (1.22 to NA) | 19.94 (4.11 to 40.28) | 11.76 (6.60 to 45.40) | 9.63 (2.66 to NA) | NA (8.21 to NA) | 9.43 (2.60 to 27.83) | NA (8.18 to NA) | NA (NA to NA) |
Median overall survival (in months) and range (minimum, maximum) are reported. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.
| months | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV |
|---|---|---|---|---|---|---|---|---|
| Overall Survival (Parts 1 and 2) | 23.62 (5.52 to NA) | 37.59 (15.21 to NA) | NA (18.66 to NA) | 29.60 (21.42 to 39.36) | NA (23.59 to NA) | 31.93 (8.77 to NA) | NA (36.34 to NA) | NA (NA to NA) |
Number of participants who develop postbaseline ADAs are reported. Results are presented separately for the GEA and BTC cancer groups based on Parts 1 and 2 combined and for the CRC cancer group based on Part 1 only.
| Participants | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV |
|---|---|---|---|---|---|---|---|---|
| Participants positive for treatment-emergent ADA | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants positive for treatment-induced ADA | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants negative for treatment-emergent ADA | 10 | 8 | 11 | 9 | 2 | 14 | 6 | 6 |
Pharmacokinetic (PK) parameters were assessed using noncompartmental procedures.
| ug/mL | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV |
|---|---|---|---|---|---|---|---|---|
| End of Infusion Concentration of ZW25 (Parts 1 and 2) | 365.65 ± 33.6 | 422.71 ± 24.5 | 514.39 ± 21.8 | 631.95 ± 12.5 | 545.41 ± 16.5 | 562.24 ± 17.8 | 466.48 ± 17.9 | 473.66 ± 6.8 |
Pharmacokinetic (PK) parameters were assessed using noncompartmental procedures.
| ug/mL | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV |
|---|---|---|---|---|---|---|---|---|
| Maximum Serum Concentration of ZW25 (Parts 1 and 2) | 378.05 ± 111.53 | 433.13 ± 111.80 | 524.45 ± 108.76 | 635.59 ± 77.79 | 549.07 ± 89.52 | 570.33 ± 105.06 | 471.23 ± 79.07 | 474.48 ± 32.48 |
Pharmacokinetic (PK) parameters were assessed using noncompartmental procedures.
| ug/mL | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV |
|---|---|---|---|---|---|---|---|---|
| Cycle 1 Day 15 | 61.88 ± 38.04 | 69.04 ± 28.62 | — | — | — | — | 107.26 ± 53.21 | 96.25 ± 26.60 |
| Cycle 2 Day 1 | 111.11 ± 42.53 | 92.71 ± 29.40 | 63.59 ± 35.85 | 58.60 ± 23.36 | 60.18 ± 20.54 | 125.65 ± 178.31 | 145.40 ± 54.09 | 116.63 ± 43.97 |
| Cycle 2 Day 15 | 143.35 ± 34.01 | 172.43 ± 152.82 | — | — | — | — | 182.69 ± 54.01 | 166.75 ± 34.37 |
| Cycle 3 Day 1 | — | 101.69 ± 55.74 | 43.02 ± NA | 113.47 ± 23.37 | — | 108.64 ± 39.11 | 186.38 ± 23.22 | 198.75 ± 38.24 |
| Cycle 3 Day 15 | — | 138.40 ± 50.25 | — | — | — | — | 231.80 ± 43.82 | 191.97 ± 31.43 |
| Cycle 4 Day 1 | 156.95 ± 59.21 | 168.40 ± 70.91 | 121.60 ± 38.11 | 120.06 ± 28.47 | 120.67 ± 36.62 | 133.18 ± 47.44 | 212.81 ± 24.90 | 213.50 ± 76.0 |
| Cycle 6 Day 1 | 219.18 ± 64.14 | 184.13 ± 56.14 | 157.94 ± 62.51 | 147.10 ± 45.80 | 138.80 ± 1.49 | 163.41 ± 40.41 | 199.64 ± 34.07 | 185.04 ± 37.72 |
Adverse events (AEs) were graded using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0 (v5.0).
| Participants | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV |
|---|---|---|---|---|---|---|---|---|
| Participants With At Least 1 TEAE (Part 1) | 13 | 7 | 6 | — | 2 | 6 | 6 | 7 |
| Participants With At Least 1 TEAE (Parts 1 and 2) | 13 | 11 | 11 | 9 | 2 | 15 | 6 | 7 |
Number of participants who experienced a maximum severity of Grade 3 or higher postbaseline laboratory abnormality, including either hematology or chemistry. Grades are defined using National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0.
| Participants | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV |
|---|---|---|---|---|---|---|---|---|
| Number of Participants Reporting Grade 3 or Higher Laboratory Abnormalities (Parts 1 and 2) | 8 | 7 | 6 | 2 | 0 | 10 | 2 | 1 |
Collected over Adverse events (AEs) were collected from the start of dosing of any study drug through 30 days after last study treatment or prior to beginning the next course of anticancer therapy, whichever occurs sooner, up to approximately 68 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | 9/13 (69.2%) | 4/13 (30.8%) | 13/13 (100%) |
| GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | 7/11 (63.6%) | 4/11 (36.4%) | 11/11 (100%) |
| GEA: 30 mg/kg ZW25 Q3W + XELOX | 4/11 (36.4%) | 4/11 (36.4%) | 11/11 (100%) |
| GEA: 1800/2400 mg ZW25 Q3W + XELOX | 6/9 (66.7%) | 3/9 (33.3%) | 9/9 (100%) |
| GEA: 30 mg/kg ZW25 Q3W + FP | 1/2 (50%) | 2/2 (100%) | 2/2 (100%) |
| BTC: 1800/2400 mg ZW25 Q3W + CISGEM | 7/15 (46.7%) | 7/15 (46.7%) | 15/15 (100%) |
| CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | 1/6 (16.7%) | 1/6 (16.7%) | 6/6 (100%) |
| CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Event | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV |
|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 2/13 | 0/11 | 0/11 | 0/9 | 1/2 | 0/15 | 0/6 | 1/7 |
| Bile duct stoneHepatobiliary disorders | 0/13 | 0/11 | 0/11 | 0/9 | 1/2 | 0/15 | 0/6 | 0/7 |
| Acute kidney injuryRenal and urinary disorders | 2/13 | 0/11 | 0/11 | 0/9 | 1/2 | 0/15 | 1/6 | 1/7 |
| HypokalaemiaMetabolism and nutrition disorders | 1/13 | 2/11 | 0/11 | 0/9 | 0/2 | 0/15 | 0/6 | 0/7 |
| ColitisGastrointestinal disorders | 0/13 | 0/11 | 0/11 | 0/9 | 0/2 | 1/15 | 1/6 | 0/7 |
| NauseaGastrointestinal disorders | 0/13 | 0/11 | 0/11 | 1/9 | 0/2 | 1/15 | 0/6 | 1/7 |
| VomitingGastrointestinal disorders | 1/13 | 1/11 | 0/11 | 0/9 | 0/2 | 1/15 | 0/6 | 1/7 |
| DehydrationMetabolism and nutrition disorders | 1/13 | 0/11 | 0/11 | 0/9 | 0/2 | 0/15 | 0/6 | 1/7 |
| Atrial fibrillationCardiac disorders | 0/13 | 0/11 | 0/11 | 0/9 | 0/2 | 0/15 | 0/6 | 1/7 |
| UrosepsisInfections and infestations | 0/13 | 0/11 | 0/11 | 0/9 | 0/2 | 0/15 | 0/6 | 1/7 |
| Event | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV |
|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 11/13 | 11/11 | 11/11 | 7/9 | 2/2 | 12/15 | 5/6 | 6/7 |
| NauseaGastrointestinal disorders | 12/13 | 10/11 | 8/11 | 7/9 | 2/2 | 4/15 | 4/6 | 4/7 |
| Blood creatine increasedInvestigations | 2/13 | 0/11 | 0/11 | 0/9 | 2/2 | 2/15 | 1/6 | 0/7 |
| Decreased appetiteMetabolism and nutrition disorders | 7/13 | 8/11 | 5/11 | 5/9 | 2/2 | 3/15 | 0/6 | 3/7 |
| Peripheral sensory neuropathyNervous system disorders | 7/13 | 10/11 | 7/11 | 7/9 | 0/2 | 5/15 | 5/6 | 4/7 |
| FatigueGeneral disorders | 10/13 | 9/11 | 4/11 | 5/9 | 0/2 | 2/15 | 2/6 | 4/7 |
| AnaemiaBlood and lymphatic system disorders | 7/13 | 5/11 | 3/11 | 2/9 | 0/2 | 11/15 | 2/6 | 0/7 |
| VomitingGastrointestinal disorders | 9/13 | 6/11 | 2/11 | 3/9 | 0/2 | 4/15 | 2/6 | 1/7 |
| ConstipationGastrointestinal disorders | 4/13 | 7/11 | 4/11 | 2/9 | 0/2 | 6/15 | 2/6 | 0/7 |
| HypokalaemiaMetabolism and nutrition disorders | 8/13 | 5/11 | 2/11 | 1/9 | 0/2 | 1/15 | 0/6 | 0/7 |
Baseline characteristics were assessed using the Safety Analysis Set.
| Age, Continuous(years) | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV | Total |
|---|---|---|---|---|---|---|---|---|---|
| Mean | 63.0 ± 8.84 | 61.1 ± 15.93 | 52.8 ± 10.79 | 54.3 ± 13.87 | 59.0 ± 0 | 64.0 ± 10.84 | 51.0 ± 10.55 | 58.1 ± 14.62 | 58.8 ± 12.44 |
| Sex: Female, Male(Participants) | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV | Total |
|---|---|---|---|---|---|---|---|---|---|
| Female | 2 | 1 | 2 | 2 | 0 | 5 | 3 | 1 | 16 |
| Male | 11 | 10 | 9 | 7 | 2 | 10 | 3 | 6 | 58 |
| Race/Ethnicity, Customized(Participants) | GEA: 20 mg/kg ZW25 Q2W + mFOLFOX6 | GEA: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | GEA: 30 mg/kg ZW25 Q3W + XELOX | GEA: 1800/2400 mg ZW25 Q3W + XELOX | GEA: 30 mg/kg ZW25 Q3W + FP | BTC: 1800/2400 mg ZW25 Q3W + CISGEM | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 | CRC: 1200/1600 mg ZW25 Q2W + mFOLFOX6 + BEV | Total |
|---|---|---|---|---|---|---|---|---|---|
| White | 12 | 8 | 5 | 3 | 0 | 2 | 2 | 1 | 33 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 2 | 6 | 6 | 2 | 13 | 4 | 6 | 40 |
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Aug 2019 to primary completion in Aug 2025, 72 months.
Results were first posted in Nov 2026, 1 year 2 months after primary completion.
Of 129 phase 2 interventional studies under Biliary Tract Neoplasms, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 68. This study's 72 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Zanidatamab · Cisplatin · Gemcitabine